Literature DB >> 8340065

Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide.

A Castro1, W Jiménez, J Clària, J Ros, J M Martínez, M Bosch, V Arroyo, J Piulats, F Rivera, J Rodés.   

Abstract

Impaired vascular responsiveness to angiotensin II is a common feature in human cirrhosis with ascites. The aim of this study was to investigate whether vascular reactivity to angiotensin II is also decreased in rats with carbon tetrachloride-induced cirrhosis and ascites and to assess the role of endogenous nitric oxide in this abnormality. Increasing doses of angiotensin II (from 31 to 500 ng.kg-1.min-1) induced significantly smaller increases in total peripheral resistance in conscious cirrhotic rats with ascites (n = 8) than in control animals (n = 9) at each dose tested. A reduced response to angiotensin II was also observed in vitro in aortic rings of rats with cirrhosis and ascites compared with that in control aortic rings (maximal response: 104 +/- 16 mg vs. 204 +/- 18 mg; p < 0.001). This in vitro hyporesponsiveness to angiotensin II in aortic rings of cirrhotic rats with ascites was reversed on endothelium denudation or nitric oxide synthesis inhibition with N omega-nitro-L-arginine but was not influenced by cyclooxygenase inhibition with indomethacin. In conclusion, this study shows reduced vascular reactivity to angiotensin II in carbon tetrachloride-induced cirrhosis with ascites and indicates that this abnormality is mediated by nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340065

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.

Authors:  R Wiest; S Das; G Cadelina; G Garcia-Tsao; S Milstien; R J Groszmann
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 3.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 4.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 5.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

7.  Bile acids increase intracellular Ca(2+) concentration and nitric oxide production in vascular endothelial cells.

Authors:  T Nakajima; Y Okuda; K Chisaki; W S Shin; K Iwasawa; T Morita; A Matsumoto; J I Suzuki; S Suzuki; N Yamada; T Toyo-Oka; R Nagai; M Omata
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Expression of local renin and angiotensinogen mRNA in cirrhotic portal hypertensive patient.

Authors:  Li Zhang; Zhen Yang; Bao-Min Shi; Da-Peng Li; Chong-Yun Fang; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

9.  Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis.

Authors:  Guillermo Fernández-Varo; Josefa Ros; Manuel Morales-Ruiz; Pilar Cejudo-Martín; Vicente Arroyo; Manel Solé; Francisca Rivera; Juan Rodés; Wladimiro Jiménez
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Heat shock protein 90 is responsible for hyperdynamic circulation in portal hypertensive rats.

Authors:  Jian-Hua Ai; Zhen Yang; Fa-Zu Qiu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.